Dlin-MC3-DMA: Benchmark Ionizable Cationic Liposome for Lipid Nanoparticle siRNA and mRNA Delivery

Executive Summary: Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) is an ionizable cationic liposome lipid central to lipid nanoparticle (LNP) siRNA delivery and mRNA vaccine development. (1) It exhibits up to 1000-fold greater potency in hepatic gene silencing than its precursor DLin-DMA, with ED₅₀ values as low as 0.005 mg/kg in mice. (2) Dlin-MC3-DMA's pH-dependent charge profile enables efficient endosomal escape while minimizing systemic toxicity. (3) Machine learning and molecular modeling confirm its critical role in LNP architecture and mRNA binding, outperforming other ionizable lipids in preclinical studies (Wang et al., 2022). (4) As a product of APExBIO, Dlin-MC3-DMA is extensively cited for use in LNP-mediated gene silencing, immunomodulation, and mRNA vaccine research. (5) Practical integration data and workflow parameters are summarized to maximize reproducibility and translational impact.

Biological Rationale

Lipid nanoparticle (LNP) systems are the current gold standard for delivering nucleic acids such as siRNA and mRNA in vivo. Ionizable cationic lipids are essential for encapsulation, cellular uptake, and intracellular release of these payloads. Dlin-MC3-DMA enables efficient delivery due to its ability to acquire a positive charge at acidic pH, facilitating endosomal escape, while remaining neutral at physiological pH, which reduces off-target toxicity (Wang et al., 2022). The optimal balance of charge and hydrophobicity in Dlin-MC3-DMA's structure has been refined via both empirical and computational approaches, making it a cornerstone of modern LNP technology (see comparative guide). Dlin-MC3-DMA is formulated with DSPC, cholesterol, and PEGylated lipids, supporting high encapsulation efficiency and stability for both siRNA and mRNA delivery (source).

Mechanism of Action of Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7)

Dlin-MC3-DMA is a synthetic ionizable amino lipid. At acidic pH (<6.5), such as within the endosome, its tertiary amine group becomes protonated, rendering the molecule cationic. This enables electrostatic interaction with the anionic endosomal membrane, destabilizing the membrane and promoting the release of encapsulated nucleic acids into the cytoplasm (Wang et al., 2022). At physiological pH (7.4), Dlin-MC3-DMA is largely neutral, thus reducing hemolysis and systemic toxicity. Molecular modeling studies show that Dlin-MC3-DMA aggregates to form LNPs that efficiently bind and protect mRNA/siRNA, with mRNA molecules winding around the LNP surface, optimizing delivery efficiency and payload protection (molecular model). This mechanism is distinct from permanently charged cationic lipids, which can cause off-target interactions and toxicity.

Evidence & Benchmarks

• DLin-MC3-DMA-based LNPs outperform those with SM-102 in murine mRNA vaccine delivery, inducing higher IgG titers at N/P ratios of 6:1 (Wang et al., 2022, DOI).
• Dlin-MC3-DMA achieves ED₅₀ values of 0.005 mg/kg (mice) and 0.03 mg/kg (non-human primates) for transthyretin (TTR) gene silencing (Original Product Data, APExBIO).
• mRNA-LNPs using Dlin-MC3-DMA show >90% knockdown of hepatic Factor VII expression in vivo, with minimal off-target toxicity at therapeutic doses (see biomedical scenarios).
• Solubility of Dlin-MC3-DMA is ≥152.6 mg/mL in ethanol but negligible in water and DMSO, informing solvent selection for formulation (APExBIO Product Sheet, URL).
• Machine learning (LightGBM) models, validated by animal experiments, identify Dlin-MC3-DMA as a critical substructure for LNP efficacy, supporting in silico screening of future lipid candidates (Wang et al., 2022, DOI).
• LNPs formulated with Dlin-MC3-DMA, DSPC, cholesterol, and PEG-DMG display high colloidal stability and reproducibility across batches (see integration parameters).

Applications, Limits & Misconceptions

Applications:

• Lipid nanoparticle siRNA delivery targeting hepatic genes for gene silencing, including Factor VII and TTR (Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7)).
• mRNA vaccine formulation, validated in preclinical models of infectious disease and immunotherapy (Wang et al., 2022).
• Cancer immunochemotherapy via LNP-mediated delivery of immunomodulatory nucleic acids (updates computational insights).
• Immunomodulatory research and gene therapy, where efficient cytosolic delivery and endosomal escape are required (expands translational guidance).

Common Pitfalls or Misconceptions

• Not Compatible with Aqueous or DMSO-Only Solvents: Dlin-MC3-DMA is insoluble in water and DMSO; use ethanol for stock solutions (≥152.6 mg/mL).
• Not Universally Non-Toxic: While less toxic than permanently charged cationic lipids, Dlin-MC3-DMA can exhibit toxicity at high doses or improper formulation conditions.
• Not a Standalone Delivery Agent: Dlin-MC3-DMA requires co-formulation with DSPC, cholesterol, and PEG-DMG for optimal LNP formation.
• Not Stable at Room Temperature: Must be stored at –20°C or below; prepared solutions should be used promptly to avoid degradation.
• Not Effective Outside pH-Dependent Window: pH-dependent ionization is essential for function; neutral pH impairs endosomal escape efficacy.

Workflow Integration & Parameters

Formulation Protocols: Dlin-MC3-DMA is typically dissolved in ethanol and mixed with DSPC, cholesterol, and PEG-DMG at defined molar ratios (commonly 50:10:38.5:1.5, respectively). The mixture is rapidly combined with an aqueous nucleic acid solution under controlled conditions (e.g., 25°C, pH 4.0–5.0) to form nanoparticles via microfluidics or ethanol injection (see integration parameters). LNPs should be dialyzed into a suitable buffer (e.g., PBS, pH 7.4) before use. Dlin-MC3-DMA-based LNPs show batch-to-batch reproducibility and high encapsulation efficiency (>90%) when prepared under these conditions. Store lipid stocks at –20°C and use freshly prepared solutions to minimize degradation. For additional workflow guidance, consult APExBIO’s technical documentation and mechanistic modeling benchmarks, which detail predictive modeling and integration best practices. This article clarifies the practical limits and optimized parameters of Dlin-MC3-DMA integration, extending upon the basic mechanistic insights in prior reviews.

Conclusion & Outlook

Dlin-MC3-DMA, as supplied by APExBIO (SKU A8791), represents a foundational advance in lipid nanoparticle-mediated gene silencing and mRNA delivery. Its atomic mechanism, validated by both experimental and computational evidence, underpins high gene silencing efficiency and translational potential. Ongoing developments in machine learning-guided lipid design and large-scale manufacturing are expected to further enhance the clinical impact and versatility of Dlin-MC3-DMA-based systems. Researchers are advised to leverage current benchmarks and workflow parameters to maximize reproducibility, safety, and efficacy in preclinical and clinical applications. For up-to-date technical details and product sourcing, visit the A8791 kit page.